CD44 and glioma: Furthermore, the CHR + TMZ combination also significantly reduced the expression of stem cell markers CD133 and Nanog (Deldar Abad Paskeh et al., 2021), and countered TMZ-induced increases in CD44, suggesting CHR mitigates glioma progression by reducing stem-cell characteristics (Raina et al., 2024).